This research examines whether metformin, a common diabetes drug, can improve social cognition in individuals with multiple sclerosis by promoting remyelination. Since MS damages nerve insulation, affecting brain function, the study explores whether treating co-occurring diabetes can reduce inflammation and symptoms, potentially leading to new regenerative therapies and improved quality of life.

My research investigates AU403, a novel LXR agonist, as a potential treatment for frontotemporal dementia. Using mouse brain slice models, the study shows that AU403 restores damaged myelin, improves neuronal communication, and reverses disease-like symptoms, offering hope for a condition with no approved therapies.